Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Banning ultra-processed foods brings major hurdles for public schools

Starting in July 2029, public schools are required to start phasing out ultra-processed foods under a new California law that prohibits schools from serving foods high in sugar, fat, salt and certain artificial food additives.

28 Sep 2026

New diabetes pill orforglipron achieves uniform weight loss for women of all ages

New analyses to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) show that the new daily oral weight loss / type 2 diabetes medication orforglipron was associated with similar weight loss for women of different ages and at different life stages – premenopausal, experiencing menopause, or post-menopausal.

28 Sep 2026

Research makes strong case for broader use of GLP1 drugs to protect hearts

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health.

28 Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

28 Sep 2026

New EASD study highlights red meat sugar as independent risk factor for type 2 diabetes

Preliminary results of an observational study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2), reveal that a sugar called dietary N-glycolylneuraminic acid (Neu5Gc), which is common in red meat, is independently associated with a 63% higher risk of developing type 2 diabetes (T2D) in those with the highest versus lowest consumption, even after taking into account other T2D risk factors such as level of physical activity, overall diet, smoking status and other health conditions.

28 Sep 2026

Exam stress significantly raises blood sugar levels in medical students

Exam stress is associated with significant increases in blood sugar levels in medical students both during exams and the days leading up to them, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

New study tracks rising heart and kidney risks in people with type 2 diabetes

The risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, following a type 2 diabetes (T2D) diagnosis increases substantially over time, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

Cutting ultra-processed foods and exercising slashes diabetes risk

Eating a diet low in ultra-processed foods (UPFs) and exercising can cut the risk of type 2 diabetes, even in those with a strong genetic disposition to the condition, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) suggests.

27 Sep 2026

Neurodivergent youth face higher risk of early-onset type 2 diabetes

People with neurodiversity, particularly autism and ADHD (attention-deficit/hyperactivity disorder), may be more likely to be diagnosed with type 2 diabetes (T2D) at younger ages, with particularly high prevalence of neurodiversity observed among individuals diagnosed with T2D before the age of 20, finds an analysis of patient data being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (September 28–October 2.

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026

Intuitive eating may be linked to more than a healthier relationship with food

A cross-sectional study of 1,057 U.S. adults examined how intuitive eating relates to stress, sleep, physical activity, substance use, diet, self-rated health, and self-reported cardiometabolic conditions. Higher intuitive eating scores were associated with several favorable health indicators, although the study cannot establish causality or determine the direction of these relationships.

25 Sep 2026

GLP-1s linked to nutritional deficiencies in children

Children prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes are at risk for nutritional deficiencies – diagnosed in nearly one in six patients (16.8%) within the first year – according to a new study published in the journal Childhood Obesity.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

GLP-1 drugs may influence chronic pain through gut-brain and immune pathways

Researchers reviewed evidence linking GLP-1 and GLP-1 receptor agonists to chronic pain modulation through gut microbial, neuroimmune, vagal, and metabolic pathways, with the strongest clinical evidence currently involving knee osteoarthritis and idiopathic intracranial hypertension headache. Much of the proposed biology remains supported by preclinical research, and human studies have yet to establish that GLP-1RA-induced changes in the gut microbiome directly cause pain relief.

24 Sep 2026

Semaglutide’s heart benefits may extend beyond weight loss

Semaglutide is known to reduce the risk of serious heart disease. However, a new study published in the European Heart Journal today (Thursday) suggests that this effect cannot not be entirely explained by patients losing weight on the drug.

23 Sep 2026

Diabetes medication adherence remains low among disadvantaged patients

A new study led by UCLA Health found that a large percentage of disadvantaged patients are not taking their diabetes medications consistently.

23 Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

23 Sep 2026

Cancer incidence rises faster among people with type 2 diabetes

A nationwide study being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found that people with type 2 diabetes (T2D) have a higher risk of developing cancer, with cancer incidence rising more among people with T2D than those without diabetes over the past 25 years, largely driven by obesity-related cancers.

22 Sep 2026

New spin-out launches technology to revolutionize hormone disorder diagnosis

The University of Birmingham and Imperial College London have announced the launch of Intelligent Mass Spec Solutions Ltd (IMS Solutions), a new spin-out that is set to revolutionize diagnosis of conditions featuring disordered steroid hormone metabolism.

22 Sep 2026

Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).

From Siemens Healthineers 22 Sep 2026